ACCESSWIRE
19 Sep 2023, 21:44 GMT+10
LEXINGTON, MA / ACCESSWIRE / September 19, 2023 / Hyku Biosciences, Inc. (Hyku) today announced its launch with $56 million in seed financing to develop precision covalent medicines in oncology. Hyku is deploying an innovative chemoproteomics platform that selectively disarms disease-causing proteins by covalently targeting ligandable amino acids such as histidines, tyrosines or lysines. Hyku was incubated by RAVen, RA Capital Management's company creation engine, and is based on groundbreaking chemoproteomics research at the University of Virginia by its scientific founder, Dr. Ku-Lung (Ken) Hsu. Dr. Hsu is a recipient of The Mark Foundation's Emerging Leader Award and currently The Stephen F. and Fay Evans Martin Endowed Associate Professor of Chemistry at The University of Texas at Austin.
'Hyku was created with a singular focus to improve patient lives using the power of covalent medicines. Hyku's innovative and unique platform integrates chemoproteomics, proprietary chemistry and bespoke computational and machine-learning algorithms to target critically important amino acids such as histidines, tyrosines and lysines to expand the druggable proteome. We are proud to have a team of accomplished scientists led by our CSO, Mark Mulvihill, PhD, to achieve Hyku's vision.' said Milind Deshpande, Ph.D., Founder, Acting CEO of Hyku and Venture Partner at RA Capital Management.
'Recent progress in covalent medicine has focused largely on targeting cysteines - Hyku builds on that progress, but now targeting proteins and sites only accessible with non-cysteine covalent chemistry,' said Laura Tadvalkar, Ph.D., Managing Director at RA Capital Management and Hyku Board member. 'We are proud to see the progress Hyku has made since its inception.'
'We believe that precision covalent medicines provide a promising approach to address current and emerging challenges in oncology. Hyku's in-house chemoproteomics platform allows the team to make rapid progress across a range of pipeline programs - both internal and potentially with partners in the future. We look forward to working with the Hyku team and support their bold vision,' said Matthias Van Woensel, Ph.D., Partner at Droia Ventures and Hyku Board member.
About Hyku Biosciences
Hyku Biosciences is a biotechnology company, based in the greater Boston area, building the leading covalent medicines discovery platform to inhibit disease targets which are challenging to address with conventional approaches. Hyku's drug discovery engine is based on its proprietary platform technologies, which identifies histidine, tyrosine and lysine based binding pockets and enables rational drug design for therapeutic development. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase druggability across many target classes, and bring significant therapeutic benefits to patients via novel medicines. For more information, visit http://www.hykubiosciences.com
Contact:
SOURCE: Hyku Biosciences, Inc.
Get a daily dose of Bristol Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Bristol Star.
More InformationLONDON, UK: This week, the Global Financial Centers index showed that New York remains the world's leading financial center, with ...
Los Angeles [US], October 3 (ANI): British actor Jodie Turner-Smith has filed for divorce to end her marriage to Canadian ...
Panama City [Panama], October 3 (ANI): India's ambassador to Panama Sumit Seth paid floral tribute at the Gandhi statue on ...
New York [US], October 3 (ANI): India's Consulate General in New York on Monday celebrated Gandhi Jayanti and the International ...
London [UK], October 3 (ANI): The United Kingdom has awarded three UK companies a 4 billion pound ( USD 4.9 ...
london - Two scientists who jointly worked on the ground-breaking technology behind some of the most effective COVID-19 vaccines have ...
JAKARTA, Indonesia - According to Asian diplomats and the Philippines' president, Southeast Asian leaders have decided that Myanmar will not ...
NEW LONDON, Connecticut: Video footage taken deep in the Pacific Ocean provided the first detailed view of three World War ...
CUSTER STATE PARK, South Dakota: As part of an annual effort to maintain the health of the species, which has ...
TASHKENT, Uzbekistan: Uzbek authorities said a powerful explosion on September 28 at a warehouse near Tashkent's airport killed one person ...
TALLAHASSEE, Florida: The Florida Lottery said this week that the second-largest lottery winner in U.S. history has come forward to ...
LONDON, UK: This week, the Global Financial Centers index showed that New York remains the world's leading financial center, with ...